Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has announced a quarterly cash dividend of $0.80 per share. The dividend will be paid on July 21, 2025, to shareholders who are on record as of July 7, 2025. This regular dividend declaration demonstrates Quest's commitment to providing consistent returns to its shareholders.

A new Quest Diagnostics (DGX) report reveals concerning trends in cancer care, with 76% of oncologists reporting increased advanced cancer cases. Among these, 75% attribute this rise to screening barriers. The report highlights significant challenges in detecting cancer recurrence, with 79% of oncologists encountering cases where recurrence was missed in earlier stages. Key findings show that 68% of cases were missed due to delayed follow-up care, while 50% cite limitations in current imaging tests. The study emphasizes the potential of circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing, with 94% of oncologists believing it could reduce diagnosis delays. Quest's Haystack MRD™ test has shown promising results, detecting treatment response 1.4 months faster than traditional methods. However, broader adoption faces barriers including insurance coverage and the need for more clinical evidence.

Quest Diagnostics (NYSE: DGX) reported strong Q1 2025 financial results with revenues of $2.65 billion, up 12.1% from 2024. The company achieved reported diluted EPS of $1.94 (up 12.8%) and adjusted diluted EPS of $2.21 (up 8.3%).

Key performance metrics include:

• Diagnostic Information Services revenues increased 12.7% to $2.59 billion
• Operating income rose 15.4% to $346 million
• Net income grew 13.2% to $220 million
• Cash from operations doubled to $314 million

Quest reaffirmed its full-year 2025 guidance with:

• Expected revenues between $10.70-10.85 billion
• Projected revenue growth of 8.4-9.9%
• Updated reported diluted EPS guidance of $8.62-8.87
• Maintained adjusted diluted EPS guidance of $9.55-9.80

Quest Diagnostics (NYSE: DGX) has launched AD-Detect™, a new laboratory blood test designed to confirm amyloid brain pathology in Alzheimer's disease patients with mild cognitive impairment or dementia. The test combines blood levels of amyloid beta 42/40 and p-tau217 to produce the AD-Detect Likelihood Score™.

Research presented at the 2025 AAN Annual Meeting demonstrated the test's 91% sensitivity and specificity, with positive and negative predictive values of 89% in mild cognitive impairment populations. The test showed strong performance in real-world specimens, categorizing 42% as high likelihood, 51% as low likelihood, and 7% as indeterminate for PET positivity.

The test is now available nationwide (except New York) through Quest's network of approximately 8,000 patient access points. This blood-based test offers a more affordable and less invasive alternative to traditional amyloid PET imaging and cerebral spinal fluid testing.

Quest Diagnostics (NYSE: DGX) has launched a new FDA-cleared HPV self-collection solution for cervical cancer screening. The service allows patients to collect their own specimens in healthcare settings and will be available at Quest's 2,000 patient service centers starting next month.

The solution utilizes Roche's FDA-cleared HPV self-collection technology, approved for use with their cobas® HPV test in May 2024. This initiative follows Quest's successful launch of self-collection services for STIs in October 2024.

The self-collection option comes at no extra charge and aims to address the declining screening rates, with 4.4 million fewer American women receiving screenings in 2021 compared to 2019. The service is not FDA approved for at-home collection and is not intended to replace regular pelvic examinations.

Quest Diagnostics (NYSE: DGX) has scheduled the release of its first quarter 2025 financial results for Tuesday, April 22, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results.

Participants can join the call by dialing 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) using passcode '7895081'. The earnings release and webcast will be available on Quest's investor website. A replay will be accessible until May 6, 2025, via the website or by phone at 866-361-4757 (domestic) or 203-369-0183 (international).

Quest Diagnostics (NYSE: DGX) outlined its strategic vision at its 2025 Investor Day, projecting 4-5% compound annual revenue growth and 7-9% adjusted EPS growth beyond 2025. The company's growth strategy focuses on expanding market access in physician and hospital channels, achieving double-digit growth in advanced diagnostics across five key clinical areas, and leveraging strategic partnerships.

Key initiatives include driving growth through diagnostic innovation, expanding hospital collaborative lab solutions, growing consumer-initiated testing via questhealth.com, and focusing on advanced diagnostics in oncology, cardiometabolic health, women's health, brain health, and autoimmune disorders. The company aims to achieve 3% annual productivity savings through its Invigorate initiative and modernize IT systems through Project Nova.

For Q1 2025, Quest expects weather-related impacts to create a $25 million revenue headwind and approximately $0.10 EPS impact.

Quest Diagnostics (NYSE: DGX) has announced a strategic collaboration with Google Cloud to enhance its data management and customer experience using generative AI technology. The partnership, announced on March 18, 2025, will utilize Google's Agentspace platform to connect employees and customers with enterprise-wide knowledge and automate complex tasks.

Quest will implement Google Cloud's data analytics and AI capabilities across various operations, including R&D, customer experience, and operations, with robust data privacy safeguards. The collaboration aims to help patients better understand their laboratory data and assist physicians in providing more personalized care.

With Quest processing over 200 million test requisitions and managing more than 80 billion datapoints in 2024, the partnership will leverage Google Cloud's HIPAA-compliant infrastructure and secure data storage. This initiative builds upon Quest's existing AI and automation implementations in areas such as microbiology, cytology testing, specimen processing, and customer service.

Fresenius Medical Care (XETRA: FME; NYSE: FMS), a global leader in renal disease care, announced the divestment of select assets of its wholly owned Spectra Laboratories to Quest Diagnostics (NYSE: DGX). Under the agreement, Quest will acquire laboratory assets focused on renal-specific testing in the U.S. Additionally, Quest will provide comprehensive dialysis-related lab and water testing services to Fresenius Medical Care's clinics in the U.S.

This acquisition will allow Quest to enhance its portfolio with dialysis-related water testing capabilities. The deal is expected to bring operational efficiencies to Fresenius Medical Care and leverage Quest's national scale, reducing transportation times and speeding up results reporting. Financial terms were not disclosed, and the acquisition is expected to close in the second half of 2025, with service transitions completing by early 2026.

Fresenius Medical Care is in the second year of a three-year strategic turnaround plan, focusing on optimizing its portfolio by divesting non-core and dilutive assets. Chronic kidney disease affects approximately 35.5 million people in the U.S., with over 800,000 receiving dialysis. This transaction aligns with Fresenius Medical Care's strategy to concentrate on its core business of providing dialysis care.